 |
11 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- || AMG 172 / Amgen
Clinical, P1 data, PK/PD data, Journal: First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. (Pubmed Central) - Mar 4, 2020
AMG 172 exhibited a favorable pharmacokinetic profile in patients with relapsed/refractory ccRCC and showed evidence suggestive of limited antitumor activity. Safety and tolerability were as expected for a maytansinoid antibody-drug conjugate.
- | AMG 172 / Amgen
Trial completion, Trial primary completion date: AMG 172 First in Human Study in Patients With Kidney Cancer (clinicaltrials.gov) - Jan 11, 2016
P1, N=37, Completed, Sponsor: Amgen
Safety and tolerability were as expected for a maytansinoid antibody-drug conjugate. Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Nov 2014
- AMG 172 / Amgen
Enrollment closed, Enrollment change: AMG 172 First in Human Study in Patients With Kidney Cancer (clinicaltrials.gov) - Jun 16, 2015
P1, N=37, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Nov 2014 Recruiting --> Active, not recruiting | N=82 --> 37
- || AMG 172 / Amgen
Enrollment change, Trial primary completion date: AMG 172 First in Human Study in Patients With Kidney Cancer (clinicaltrials.gov) - Oct 22, 2014
P1, N=82, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=82 --> 37 N=60 --> 82 | Trial primary completion date: Apr 2015 --> Dec 2015
- || AMG 172 / Amgen
Trial primary completion date: AMG 172 First in Human Study in Patients With Kidney Cancer (clinicaltrials.gov) - Jul 21, 2014
P1, N=60, Recruiting, Sponsor: Amgen
N=60 --> 82 | Trial primary completion date: Apr 2015 --> Dec 2015 Trial primary completion date: Apr 2014 --> Apr 2015
- ||| AMG 172 / Amgen
New P1 trial: AMG 172 First in Human Study in Patients With Kidney Cancer (clinicaltrials.gov) - Dec 21, 2011
P1, N=60, Recruiting, Sponsor: Amgen